Extended Bolus for Meals in a Closed-loop System

Last updated: June 9, 2025
Sponsor: University of California, San Francisco
Overall Status: Active - Recruiting

Phase

4

Condition

Diabetes Mellitus Types I And Ii

Diabetes And Hypertension

Diabetes Mellitus, Type 1

Treatment

Standard bolus of insulin then extended bolus of insulin

Extended bolus of insulin then standard bolus of insulin

Clinical Study ID

NCT05454891
58992
5K23DK121942-02
  • Ages 13-19
  • All Genders

Study Summary

This study aims to evaluate whether the use of an extended bolus will improve glucose control with high-fat high protein meals using a closed-loop system. The new knowledge gained from this study may provide a method to allow for the proper administration of insulin over an extended period to mitigate the risk of prolonged hyperglycemia or early hypoglycemia.

Eligibility Criteria

Inclusion

Inclusion Criteria

  • Age between 13 and 19 years old, A1C > 6% at screening

  • Diagnosed with type 1 diabetes for at least one year

  • Total daily dose (TDD) of insulin ≥ 0.3 units/kg/day

  • Currently using the Control IQ closed-loop system

  • Willing to abide by meal recommendations and study procedures

  • Willing and able to sign the Informed Consent Form (ICF) and/or has a parent or guardian willing and able to sign the ICF

  • Use an Android or Apple smartphone

  • Willingness not to start any new non-insulin glucose-lowering agent during the course of the trial

  • Participant and parent(s)/guardian(s) willingness to participate in all training sessions as directed by study staff

  • Parent/guardian proficient in reading and writing English

  • Live in the United States, with no plans to move outside the United States during the study period

Exclusion Criteria

  • A1C >10%

  • One or more episodes of severe hypoglycemia or DKA requiring ER visit or hospitalization within the past three months

  • Used non-insulin anti-diabetic medication within the last 30 days other than metformin

  • Known history of gastroparesis, seizure disorder, adrenal insufficiency, or ongoing renal or hepatic disease

  • Pregnancy or lactation

  • Untreated or unstable hypothyroidism

  • Currently undergoing cancer treatment or systemic treatment with steroids

  • Untreated or inadequately treated mental illness

  • Current alcohol abuse

  • Current illness that would interfere with participation in the study

  • Delayed gastric emptying or any concurrent conditions that can be associated with delayed gastric emptying or altered digestion; and the use of any medication that affects gastric emptying

  • Celiac Disease

Study Design

Total Participants: 30
Treatment Group(s): 2
Primary Treatment: Standard bolus of insulin then extended bolus of insulin
Phase: 4
Study Start date:
July 15, 2022
Estimated Completion Date:
September 30, 2025

Connect with a study center

  • University of California San Francisco

    San Francisco, California 94158
    United States

    Active - Recruiting

Not the study for you?

Let us help you find the best match. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.